Skip to Content

Abliva AB - Stock Quote ABLI

Rating as of

Morningstar's Abliva AB Stock Analysis

Valuation
Currency in SEK
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Abliva AB's Company Profile

Business Description

Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase.

Contact
Scheelevagen 2, Medicon Village
Lund, SE-223 81, Sweden
T +46 462756220
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2021
Fiscal Year End Dec 31, 2022
Stock Type
Employees 8